RxDoctor Payments Data

Li Nguyen, MD

Plastic and Reconstructive Surgery · Westminster, CANPI 1902989064

Payments from drug & device makers

$2,018in general payments, 2019–2025

Across 63 payments — averaging $32.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$857
  • GSK$366
  • Sanofi$175
  • Pharmacyclics LLC, An Abbvie Company$125
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$118
  • Regeneron Healthcare Solutions, Inc.$94
  • plus $284 from 9 others

What the payments were for

  • Food & beverage$2,018100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,018 in reported general payments places this provider in the 50th percentile of 349 plastic and reconstructive surgery providers in California.

See all plastic and reconstructive surgery providers in California

Medicare billing

Part B allowed, 2024
$219,385
Medicare patients
356
Services billed
22,195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate26$16,130
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth97$11,501
Fluticasone Propionate565$5,678
Esomeprazole Magnesium103$2,182
Ofloxacin49$1,912
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort34$1,728
Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort36$1,567
Mometasone Furoate45$801
Azelastine Hcl21$401
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav44$346
Oseltamivir Phosphate11$279
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid64$176
Azithromycin49$138
Meclizine Hcl28$112
Omeprazole35$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$857$16,13026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 349 plastic and reconstructive surgery providers in California.

Other plastic and reconstructive surgery in Westminster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →